Climb Bio (NASDAQ:CLYM) Now Covered by Analysts at B. Riley Financial

B. Riley Financial initiated coverage on shares of Climb Bio (NASDAQ:CLYM) in a research report report published on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $26.00 price objective on the stock.

A number of other research firms have also issued reports on CLYM. Robert W. Baird upped their price target on Climb Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. Raymond James Financial started coverage on Climb Bio in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $25.00 price objective on the stock. Wedbush initiated coverage on Climb Bio in a research note on Thursday, March 5th. They set an “outperform” rating and a $12.00 price objective on the stock. Piper Sandler started coverage on Climb Bio in a report on Friday, February 13th. They issued an “overweight” rating for the company. Finally, Truist Financial started coverage on Climb Bio in a research note on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Climb Bio has a consensus rating of “Buy” and a consensus target price of $15.63.

Climb Bio Trading Up 2.1%

CLYM opened at $6.68 on Tuesday. Climb Bio has a twelve month low of $1.05 and a twelve month high of $8.04. The firm has a market capitalization of $319.10 million, a PE ratio of -7.51 and a beta of -0.25. The firm’s 50-day moving average price is $5.87 and its 200 day moving average price is $3.73.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). As a group, analysts predict that Climb Bio will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new position in Climb Bio in the first quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Climb Bio in the third quarter valued at $29,000. Qube Research & Technologies Ltd acquired a new position in shares of Climb Bio in the 2nd quarter valued at $43,000. Virtu Financial LLC acquired a new stake in shares of Climb Bio during the 4th quarter worth about $43,000. Finally, Blair William & Co. IL acquired a new stake in shares of Climb Bio during the 4th quarter worth about $44,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.